Taking T-Cell Oncotheraphy Off-the-Shelf

被引：15

作者：

Mo, Feiyan ^{[1
,2
,3
]}

Mamonkin, Maksim ^{[1
,2
,3
,4
,5
]}

Brenner, Malcolm K. ^{[1
,2
,3
,5
]}

Heslop, Helen E. ^{[1
,2
,3
,5
]}

机构：

[1] Texas Childrens Hosp, Ctr Cell & Gene Therapy, Baylor Coll Med, Houston, TX 77030 USA

[2] Houston Methodist Hosp, Houston, TX 77030 USA

[3] Baylor Coll Med, Grad Program Translat Biol & Mol Med, Houston, TX 77030 USA

[4] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA

[5] Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, Houston, TX 77030 USA

来源：

TRENDS IN IMMUNOLOGY | 2021年 / 42卷 / 03期

关键词：

CHIMERIC-ANTIGEN-RECEPTOR; MINOR HISTOCOMPATIBILITY ANTIGENS; NATURAL-KILLER-CELLS; VERSUS-HOST-DISEASE; NK CELLS; IMMUNOTHERAPY; CAR; EXPRESSION; PLATFORM; TUMOR;

D O I：

10.1016/j.it.2021.01.004

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Banked allogeneic or 'off-the-shelf' (OTS) T cells from healthy human donors are being developed to address the limitations of autologous cell therapies. Potential challenges of OTS T cell therapies are associated with their allogeneic origin and the possibility of graft-versus-host disease (GvHD) and host-versus-graft immune reactions. While the risk of GvHD from OTS T cells has been proved to be manageable in clinical studies, approaches to prevent immune rejection of OTS cells are at an earlier stage of development. We provide an overview of strategies to generate OTS cell therapies and mitigate alloreactivity-associated adverse events, with a focus on recent advances for preventing immune rejection.

引用

页码：261 / 272

页数：12

共 50 条

[31] Enhanced Generation of T-Cell Derived Naive Pluripotent Cells as a Renewable Cell Source for the Mass Manufacture of Off-the-Shelf CAR T Cell Therapies
Lai, Yi-Shin
Hsu, Hui-Ting
Pribadi, Mochtar
Bonello, Greg
Robinson, Megan
Tsai, Pei-Fang
Yang, Bi-Huei
Hsia, Gloria
Yzaguirre, Amanda
Clarke, Raedun
Lee, Tom
Abujarour, Ramzey
Valamehr, Bahram
MOLECULAR THERAPY, 2021, 29 (04) : 38 - 38
[32] Rejection-Resistant Off-The-Shelf T Cells for Adoptive Cell Therapy
Mo, Feiyan
Srinivasan, Madhuwanti
Ma, Royce
Smith, Tyler S.
McKenna, Mary K.
Atilla, Erden
Atilla, Pinar Ataca
Heslop, Helen E.
Brenner, Malcolm K.
Mamonkin, Maksim
MOLECULAR THERAPY, 2019, 27 (04) : 64 - 64
[33] Rejection-Resistant Off-the-Shelf T Cells for Adoptive Cell Therapy
Mo, Feiyan
Srinivasan, Madhuwanti
Heslop, Helen E.
Brenner, Malcolm K.
Mamonkin, Maksim
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2019, 25 (03)
[34] Off-the-shelf tumor immunotherapy with genetically enhanced allogeneic T cell precursors
Zakrzewski, Johannes L.
Suh, David
Markley, John
King, Christopher
Smith, Odette M.
Goldberg, Gabrielle
Jenq, Robert
Holland, Amanda M.
Lu, Sydney
Sant'Angelo, Derek
Riviere, Isabelle
Sadelain, Michel
van den Brink, Marcel R. M.
FASEB JOURNAL, 2008, 22
[35] A novel strategy for off-the-shelf T cell therapies evading host T cell and NK cell rejection
Zhang, Y.
Goel, S.
Prodeus, A.
Jetley, U.
Tan, Y.
Averill, J.
Ranade, U.
McMichael, E.
Foisey, M.
Balwani, I.
Liu, D.
Dutta, I.
Sharma, P.
Roy, M.
O'Connell, D.
Keenan, M.
Lescarbeau, R.
Schultes, B.
HUMAN GENE THERAPY, 2021, 32 (19-20) : A8 - A8
[36] Off-the-shelf measurements
不详
MECHANICAL ENGINEERING, 2002, 124 (10) : 31 - 31
[37] DIY or off-the-shelf?
Diane Gershon
Nature, 2002, 416 : 887 - 887
[38] Off-the-shelf reactors
Prof. Eng., 2008, 22 (43):
[39] Off-the-shelf "holos"
Ditlea, S
COMPUTER GRAPHICS WORLD, 2001, 24 (10) : 36 - +
[40] Off-the-shelf autos
Ferguson, TW
Power, JD
FORBES, 1997, 159 (03): : 44 - 45

← 1 2 3 4 5 →